Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEPTOCAINE vs LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Articaine is a local anesthetic of the amide type that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also has antiarrhythmic properties by decreasing automaticity in Purkinje fibers and suppressing ventricular arrhythmias.
Local infiltration anesthesia for dental procedures,Nerve block anesthesia for dental procedures
Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia,Treatment of acute ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation) in the setting of myocardial infarction or cardiac surgery (off-label use of lidocaine),Status epilepticus (off-label use)
SEPTOCAINE (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) dental infiltration or nerve block: 0.5–1.7 m L (20–68 mg articaine) per injection site; maximum adult dose: 7 mg/kg (up to 500 mg total).
Intrathecal administration for spinal anesthesia: 50-100 mg (1.5-2 m L of 5% solution) as a single dose. For continuous epidural or peripheral nerve block, 0.8% solution with dextrose 5% is not typically used; refer to 1-2% lidocaine without dextrose for continuous infusion.
Terminal elimination half-life in adults is 2-4 hours. In neonates, it may be prolonged to 8-12 hours due to immature hepatic function.
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 5-8 hours) or hepatic impairment (up to 10-15 hours). Clinically, context indicates redistribution half-life ~8 minutes.
No specific dose adjustment for mild-to-moderate renal impairment; caution in severe renal impairment (GFR <30 m L/min) with extended monitoring for methemoglobinemia.
No dose adjustment required for renal impairment. Lidocaine is extensively hepatically metabolized; <10% excreted unchanged in urine. GFR-based modifications are not necessary.
Not FDA approved for use in children under 4 years of age. Methemoglobinemia has been reported; risk increases with total dose and in patients with glucose-6-phosphate dehydrogenase deficiency.
Septocaine (articaine with epinephrine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm at doses 1.3 to 2.6 times the maximum recommended human dose, but no adequate human studies exist. Risk cannot be ruled out. Use only if potential benefit justifies potential risk. First trimester: Avoid elective procedures; risk of teratogenicity cannot be excluded. Second and third trimesters: Use with caution; potential for fetal bradycardia due to epinephrine or maternal hypotension.
First trimester: No evidence of teratogenicity in humans; lidocaine crosses placenta but not associated with major malformations. Second trimester: Low risk; use only if clearly needed. Third trimester: Potential for neonatal CNS depression and bradycardia if high maternal serum levels; epidural use may cause fetal bradycardia. Avoid in fetal distress or uteroplacental insufficiency.
SEPTOCAINE (articaine HCl with epinephrine) is a dental local anesthetic. The 1:100,000 epinephrine concentration provides hemostasis. Avoid in patients with sulfite allergy (contains sodium metabisulfite). Maximum dose: 7 mg/kg articaine, 0.2 mg epinephrine per appointment. Use aspiration to prevent intravascular injection. Onset: 1-3 min; duration: 60-75 min for pulp, 180-300 min for soft tissue.
Lidocaine hydrochloride 0.8% and dextrose 5% is a hyperbaric solution used for spinal anesthesia. The baricity (1.029-1.031 at 20°C) ensures predictable spread in cerebrospinal fluid. Administer with patient in lateral or sitting position; position changes can alter block height. Use for lower abdominal, pelvic, perineal, and lower extremity procedures. Contraindicated in patients with complete heart block, severe hypotension, or hypersensitivity to amide anesthetics. Rapid injection can cause high spinal block; monitor for respiratory compromise. Epinephrine may prolong duration but is not included in this preparation.
No interactions on record
No interactions on record
SEPTOCAINE and LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER are distinct pharmacological agents. SEPTOCAINE belongs to the Local Anesthetic class and is primarily used for Local infiltration anesthesia for dental proceduresNerve block anesthesia for dental procedures. LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER belongs to the Local Anesthetic / Antiarrhythmic (Class Ib) class and is primarily used for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesiaTreatment of acute ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation) in the setting of myocardial infarction or cardiac surgery (off-label use of lidocaine)Status epilepticus (off-label use). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SEPTOCAINE carries a safety status of Category C, whereas LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily metabolized by plasma esterases (nonspecific) and hepatic CYP450 enzymes (minor).
Lidocaine undergoes extensive hepatic metabolism primarily via CYP1A2 and CYP3A4 to active metabolites (monoethylglycinexylidide, MEGX; glycinexylidide, GX) which have antiarrhythmic and convulsant activity. Dextrose is metabolized via glycolysis and the Krebs cycle.
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Renal (metabolites: 4-hydroxyxylidine, glycylxylidide, monoethylglycinexylidide; <10% unchanged). Biliary/fecal negligible.
About 55-75% bound primarily to alpha1-acid glycoprotein.
70% bound primarily to alpha-1-acid glycoprotein (AAG); binding saturable and decreased in acidosis.
Approximately 1.0 L/kg, indicating extensive distribution into tissues.
Vd: 1.1-1.5 L/kg (total); rapid distribution to highly perfused tissues (brain, heart, liver, kidneys). Clinically indicates large tissue reservoir.
Intravenous: 100%; Subcutaneous or topical: Not applicable due to vasoconstriction and first-pass metabolism.
Intravenous: 100%. Oral: <35% (extensive first-pass metabolism). Intramuscular: 100% (bioequivalent to IV). Epidural: 70-80% (systemic absorption).
Child-Pugh A and B: no adjustment; Child-Pugh C: avoid use or reduce dose by 50% with monitoring due to reduced hepatic clearance.
Severe hepatic impairment (Child-Pugh class C): reduce dose by 50% and monitor for toxicity. Moderate impairment (Child-Pugh class B): consider 25% dose reduction. Mild impairment (Child-Pugh class A): no adjustment needed.
Pediatric weight-based dosing: articaine 4% with epinephrine 1:100,000 or 1:200,000; maximum dose 7 mg/kg; typical infiltration 0.5–1.7 m L per site; adjust volume to age and weight; not recommended under 4 years of age.
Not approved for pediatric use; alternative formulations or agents recommended. If used off-label, dose based on weight: 0.5-1 mg/kg for spinal anesthesia, maximum 100 mg. Must be administered by experienced provider.
Elderly: start with lower doses (minimum effective volume) due to possible decreased hepatic/renal function; maximum dose 7 mg/kg; monitor for prolonged effect and cardiovascular stress.
Elderly patients (≥65 years) may require reduced doses due to decreased clearance and increased sensitivity. Use lower effective dose (e.g., 25-50 mg spinal), titrate slowly, and monitor for hypotension and bradycardia.
There is no black box warning for lidocaine hydrochloride 0.8% and dextrose 5% in plastic container.
Methemoglobinemia risk; avoid in patients with congenital or idiopathic methemoglobinemia. Use with caution in patients with impaired cardiovascular function, hepatic or renal disease, and in elderly or debilitated patients. Contains sulfites which may cause allergic reactions including anaphylaxis.
Hypersensitivity to articaine or any component of the formulation; hypersensitivity to amide-type local anesthetics; sulfite allergy; severe hypotension; atrioventricular block; uncontrolled epilepsy; myasthenia gravis (relative).
No specific food interactions. Avoid hot foods or beverages until sensation returns to prevent burns.
No significant food interactions. The solution is administered via injection; dietary restrictions are not applicable.
Articaine is excreted into breast milk in small amounts; the milk-to-plasma ratio (M/P) is approximately 0.8. Relative infant dose is estimated at 2-5% of maternal weight-adjusted dose, considered safe. Epinephrine has poor oral bioavailability. However, monitor infant for signs of local anesthetic toxicity (e.g., irritability, drowsiness).
Lidocaine is excreted in breast milk in small amounts; M/P ratio not specifically determined for this formulation. Estimated infant dose <2% of maternal weight-adjusted dose; considered compatible with breastfeeding. Monitor infant for drowsiness or poor feeding, especially with high maternal doses or prolonged infusion.
No standard dose adjustments are required; however, use lowest effective dose. Physiological changes in pregnancy (increased plasma volume, reduced protein binding) may slightly increase free fraction of articaine, but dose reduction is not routinely recommended. Avoid intravascular injection. Maximum recommended dose: 7 mg/kg articaine, 0.001 mg/kg epinephrine. Reduce dose in preeclampsia or cardiovascular compromise.
Increased plasma volume and altered protein binding may reduce peak lidocaine concentrations; however, increased clearance (due to hepatic induction) may necessitate higher doses for pain management. Use lowest effective dose and monitor for toxicity. No standard dose adjustment; adjust based on clinical response and serum levels.
Avoid eating or drinking until numbness subsides to prevent biting your cheek or tongue.,Inform your dentist if you have a history of allergy to local anesthetics or sulfites.,Tell your dentist about all medications, especially MAOIs, tricyclic antidepressants, or beta-blockers.,Numbness may last several hours; do not test the area with sharp objects.,Seek immediate medical attention if you experience difficulty breathing, swelling, or hives.
You will receive an injection into your lower back to numb the lower half of your body.,You may feel warm, tingling, or numb in your legs and lower belly after the injection.,You will not be able to feel pain in the numbed area during your procedure.,Do not drive or operate machinery for at least 24 hours after the procedure.,Report any headache, difficulty breathing, or new back pain to your doctor immediately.,Avoid strenuous activity until the numbness fully wears off.